Serum homocysteine level and eye involvement in Egyptian patients with Behçet’s disease

The present study investigates the effect of ozagrel, a selective thromboxane A2 (TXA2) inhibitor, in rat model of hyperhomocysteinemia (HHcy)‐induced vascular cognitive impairment and dementia (VCID). Wistar rats were administered L‐methionine (1.7 g/kg/day; p.o. × 8 weeks) to induce VCID. Morris water maze (MWM) test was employed to assess learning and memory. Endothelial dysfunction was assessed in the isolated aorta by observing endothelial‐dependent vasorelaxation and levels of serum nitrite. Various biochemical and histopathological estimations were also performed. L‐methionine produced significant impairment in endothelium‐dependent vasorelaxation and decreases serum nitrite levels indicating endothelial dysfunction. Further, these animals performed poorly on MWM, depicting impairment of learning and memory. Further, a significant rise in brain oxidative stress level (indicated by increase in brain thiobarbituric acid‐reactive species and decrease in reduced glutathione levels), brain acetylcholinesterase activity, brain myeloperoxidase activity, brain TNF‐α and IL‐6 levels, and brain leukocyte (neutrophil) infiltration was also observed. Treatment of ozagrel (10 and 20 mg/kg, p. o.)/donepezil (0.5 mg/kg, i.p., serving as standard) ameliorated L‐methionine‐induced endothelial dysfunction, memory deficits, and biochemical and histopathological changes. It may be concluded that ozagrel markedly improved endothelial dysfunction, learning and memory, and biochemical and histopathological alteration associated with L‐methionine‐induced VCID and that TXA2 can be considered as an important therapeutic target for the management of VCID.

show abstract

“…The serum homocysteine level was estimated by chemiluminescent microparticle immunoassay using the method of Allam et al . [42].…”

Section: Methodsmentioning

confidence: 99%

Ameliorative effect of ozagrel, a thromboxane A2 synthase inhibitor, in hyperhomocysteinemia‐induced experimental vascular cognitive impairment and dementia

Bhatia

Singh

2020

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…5 ) that dropped to nil after removal of one outlier study that included the whole spectrum of ocular involvement. 50…”

Section: Resultsmentioning

confidence: 99%

“…The initial database search yielded 184 entries plus another 2 found on Google; following the screening and exclusion processes indicated in Fig. 1 , we identified 53 studies (52 full papers and one abstract) 6 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 examining the relationship between HC and BD (48 case–control and 5 cohort studies) that were included in our systematic review and meta-analysis ( Table 1 ). Of the 48 case–control studies, one did not report the mean ages of participants 22 and another did not report gender data (both full papers), 31 whereas a third (in abstract form only) did not report the mean ages and the gender data 40 : two missing data each for mean age of participants and for male/female ratio (4.1%) are unlikely to compromise the results of the sensitivity analysis; of the five cohort studies one did not report the mean age of participants.…”

Section: Resultsmentioning

confidence: 99%

Plasma Homocysteine in Behcet's Disease: A Systematic Review and Meta-Analysis

et al. 2022

View full text Add to dashboard Cite

Aim To evaluate the relevance of plasma homocysteine (HC) in Behcet's disease (BD) and its clinical manifestations. Methods Systematic review of EMBASE and PubMed databases according to PRISMA guidelines from inception to July 2021; random-effects meta-analyses for continuous outcomes. Results The search strategy retrieved 48 case–control (2,669 BD and 2,245 control participants) and 5 cohort studies (708 BD participants). Plasma HC was higher in BD than in controls (p < 0.0001) with wide heterogeneity (I2 = 89.7%) that remained unchanged after sensitivity analysis according to year of article publication, age of BD participants, study size, study quality, method of HC determination, and male/female ratio >1.5; some pooled ethnicities explained a small part of the heterogeneity (I2 = 16.3%). Active BD participants had higher HC than inactive ones (p < 0.0001), with moderate heterogeneity (I2 = 49.2%) that disappeared after removal of an outlier study with very high disease activity. BD participants with any vascular involvement had higher HC than those without (p < 0.0001) with wide heterogeneity (I2 = 89.7%); subgroup analysis on venous thrombosis only changed neither effect size (p < 0.0001) nor heterogeneity (I2 = 72.7%). BD participants with ocular involvement had higher HC than those without (p < 0.0001) with moderate heterogeneity (I2 = 40.3%). Conclusion Although causality cannot be inferred, the consistency of the elevation of plasma HC in BD, particularly in patients with active disease, with vascular and ocular involvement suggests an intrinsic involvement of HC in these clinical manifestations.

show abstract

“…Allam et al conducted a study on egyptian patients diagnosed with Behcet's disease which had high plasma levels of HCYS, that led to the conclusion that, in these patients, the accumulation of HCYS is directly implicated in eye injuries, such as retinal atrophy, vitreousum hemorrhage, retinal detachment and vasculopathic complications. 10 The main neurotoxic effects are caused by cytosolic calcium accumulation, which activates several neurodegenerative kinases, as a consequence to hydrogen preoxid production which can degrade DNA and potentiate neuronal beta-amyloid protein synthesis. 19 Vitamin B and folate deficiency, which are directly involved in the metabolism of methionine as cofactors, also have neurodegenerative effects.…”

Section: H-hcys and Neurological Disordersmentioning

confidence: 99%

“…3 Therefore, low cofactor concentration leads to the inhibition of the metabolic cycle. HCYS accumulation in the body (hyperhomocysteinemia, H-HCYS) entails multi-organ pathologies: neurological diseases -mental retardation, 4 cerebral atrophy, 5 seizures, 6 depression, 7 Alzheimer's disease, 8 Parkinson's disease, 9 ophthalmic abnormalities, 10 bone disease, 11 and cardiovascular disease. 12 This paper presents an update on the biochemical mechanisms and the pathophysi-ological implications of H-HCYS in patients with certain diseases, including polytrauma patients.…”

Section: Introductionmentioning

confidence: 99%

The Effects of Homocysteine Level in the Critically Ill Patient. A Review

Bedreag

Rogobete

Săndesc

et al. 2016

Journal of Interdisciplinary Medicine

View full text Add to dashboard Cite

Increased levels of homocysteine (HCYS) represent a risk factor for a series of physiopathological conditions: mental retardation, cardiovascular and neurodegenerative diseases, Parkinson's and Alzheimer's disease, depression, osteoporosis, endothelial dysfunction and inhibition of cell proliferation. This paper aims to present the pathophysiological implications of HCYS and the correlation of hyperhomocysteinemia (H-HCYS) with critical condition in the intensive care unit (ICU). Hypovitaminosis B and folate deficiency is directly involved in the inhibition of HCYS metabolism and the accumulation of HCYS in the plasma and tissues. Critically ill patients are more prone to H-HCYS due to hypermetabolism and accelerated synthesis produced by reactive oxygen species (ROS). In conclusion it can be affirmed that the determination and monitoring of HCYS plasma levels may be of interest in optimizing the therapy for critically ill patients. Moreover, by controlling HCYS levels, and implicitly the essential cofactors that intervene in the specific biochemical pathways, such as vitamin B6, vitamin B12 and folic acid can provide a diversified and personalized treatment for each patient.

show abstract

Serum homocysteine level and eye involvement in Egyptian patients with Behçet’s disease

Cited by 7 publications

References 30 publications

Ameliorative effect of ozagrel, a thromboxane A2 synthase inhibitor, in hyperhomocysteinemia‐induced experimental vascular cognitive impairment and dementia

Ameliorative effect of ozagrel, a thromboxane A2 synthase inhibitor, in hyperhomocysteinemia‐induced experimental vascular cognitive impairment and dementia

Plasma Homocysteine in Behcet's Disease: A Systematic Review and Meta-Analysis

The Effects of Homocysteine Level in the Critically Ill Patient. A Review

Contact Info

Product

Resources

About